NMN vs NR: What the Research Actually Shows

Search "NMN vs NR" and you'll find two camps that both sound completely sure of themselves. One says NMN is the more direct precursor and that's why it wins. The other says NR has better absorption data and that's why it wins. Both sides usually cite a study. So which one is actually right?

Honestly, the fairest answer is: it depends which study you're reading, and the research is still catching up to the marketing. Here's what the actual published human trials show, not just the headline someone pulled from them.

NMN vs NR: What's the Basic Difference?

Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors the body can convert into NAD+, the coenzyme cells rely on for energy metabolism. NMN and NR take slightly different routes to raising NAD+: NR is converted first into NMN and then into NAD+, while NMN is generally understood to convert more directly. In practice, that mechanistic difference hasn't translated into a clear, settled answer about which one raises NAD+ more in the human body. That's exactly what the two studies below tried to test directly.

NMN vs NR Study: The Largest Head-to-Head Comparison

A direct comparison comes from a study published in Nature Metabolism in January 2026 (Christen et al.), an open-label trial (participants and researchers knew which supplement each person received) that put 65 healthy adults through a randomized, placebo-controlled, four-arm design: one group took 1 gram of NR daily, one took 1 gram of NMN daily, one took 0.5 grams of nicotinamide (NAM, a related but different B3 form), and one took a placebo, for 14 days.

Both NR and NMN significantly raised whole-blood NAD+ compared with placebo. NR increased it by about 49.4 µM and NMN by about 43.1 µM, both comfortably statistically significant (p < 0.001). Nicotinamide, the third compound tested, didn't move the needle in a statistically meaningful way. The gap between NR and NMN's own results was small enough that this study doesn't support declaring either one a clear winner over the other; this is a specific biomarker finding, not a broader claim about health, energy, or longevity. Tolerability was good across the board, with only three mild, possibly-related adverse events across all 65 participants.

A Second NMN vs NR Study: The Bergen NADbrain Trial

A separate study out of Haukeland University Hospital in Bergen, Norway, the "NADbrain" study, published in iScience in 2026, looked at something the Nature Metabolism trial didn't: how NR and NMN affect NAD+ in the brain, not just the blood. It ran in two stages. The first tested 1,200 mg per day (600 mg twice daily) of either NR or NMN in six healthy adults over 8 days. The second stage continued with NR only, in six more healthy adults alongside six people with Parkinson's disease, over four weeks, as part of the researchers' own investigation into brain NAD+ in that population. It's worth being precise about that distinction: the Parkinson's participants were part of a longer-term NR-only phase, not a head-to-head NR-vs-NMN comparison, and nothing in this study or this article should be read as a claim about either supplement treating, managing, or benefiting Parkinson's disease or any other condition.

Some secondary coverage of this study's early results describes a bigger gap in NR's favor than the Nature Metabolism trial did, over the first 8-day stage. We're deliberately not repeating specific percentages here: Until someone verifies the actual published numbers directly against the primary paper, we'd rather leave the specific figures out than risk repeating something that turns out to be inaccurate.

Why NMN and NR Study Results Differ

Part of the disagreement is probably just design. The two studies used different doses (1 gram vs 1.2 grams daily), different durations (14 days vs 8 days for the early blood readings), different measurement approaches, and very different sample sizes (65 people vs 6 to 12). Small early-phase studies are also more prone to results that don't hold up exactly the same way in a larger follow-up. None of that means either study is wrong. It means the honest answer, at this point, is that the research is still being worked out, not that one compound has been conclusively proven better.

It's also worth knowing that ProHealth's own Uthever® NMN trial (covered in a separate article) used yet another design entirely: a lower dose (300 mg/day), a longer duration (60 days), and a percent-change-from-baseline measurement rather than an absolute µM change. That makes it genuinely hard to place side by side with either study above. Anyone telling you these numbers all point to one clean conclusion is oversimplifying.

NMN vs NR: Which Should You Choose?

Based on the best-controlled evidence available right now, both NMN and NR are legitimate, human-research-backed options for supporting NAD+ levels, and neither has been conclusively shown to outperform the other. If brain-specific effects or use in a specific health context matter to you, that's a newer and thinner body of research, and still an open question, not settled science. As always, this is general information, not a recommendation for your specific situation, and it's a good idea to check in with a healthcare provider about what makes sense for you, especially alongside any existing conditions or medications.

If You're Leaning Toward NMN

None of the above is about talking you into one side. But if you've read this far and NMN sounds like the right fit for you, it's worth knowing what to look for: a branded ingredient with published human data behind it, and a manufacturer that's transparent about what that research does and doesn't show.

ProHealth's NMN Pro 1000™ uses Uthever® NMN, the same branded ingredient behind the clinical trial covered in our companion article on what that study actually found, and it's third-party tested in an FDA-registered, GMP-certified facility, with certificates of analysis available on request. You can see the full product details on the NMN Pro 1000™ product page, or browse the wider lineup on the NAD+ support collection.

NMN vs NR: Frequently Asked Questions

Is NR More Studied Than NMN?

Neither. Both now have multiple published human trials, including large, placebo-controlled ones. Coverage sometimes suggests one side has "more" research simply because a company selling that ingredient publicizes its own studies more heavily.

Did Any Study Find NMN or NR Didn't Work?

Nicotinamide (NAM), a related B3 compound tested alongside NR and NMN in the Nature Metabolism study, didn't produce a statistically significant NAD+ increase in that trial. NR and NMN both did.

Does a Bigger NAD+ Increase Mean Better Results?

Not necessarily, and none of the studies above claim that. Raising a blood biomarker is not the same as a proven downstream health outcome, and none of this is intended to diagnose, treat, cure, or prevent any disease.

References:

Berven, H., et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience (2026). iScience (2026)

Haukeland University Hospital / Neuro-SysMed. The NADbrain Study: A Pharmacokinetic Study of NAD Replenishment in Human Blood and Brain

Huang, H. (2022). Uthever® NMN clinical study

Trętowicz, M. M., et al. (2026). Whole-blood NAD+ levels do not reflect healthy ageing. Nature Metabolism.